Trends in the treatment outcomes for advanced colorectal cancer: An analysis at a single community hospital in Japan
- 64 Downloads
To evaluate the trends in the treatment outcomes for patients with colorectal cancer in Japan.
We performed a retrospective analysis of patients undergoing surgery for primary colorectal cancer during a 16-year period (Group A [1992–2000, n = 258]; Group B [2001–2008, n = 258]) at Fukuoka City Hospital. Because no significant differences were found in the survival rates in stage 0, I, II, and III patients between the two groups, we concentrated on examining stage IV patients.
The 3-year survival rate for stage IV patients in Group B (n = 26) was significantly higher than that in Group A (n = 31) (34.9% vs 3.9%, P < 0.05). The rate of curative resection for advanced liver metastases in Group B patients was also significantly higher than that of Group A patients (50.0% vs 13.3%, P < 0.05). As a result, the 2-year survival rate for the disease-free patients in Group B was significantly higher than that for the non-disease-free patients in Group B (46.0% vs 21.0%, P < 0.05). Group B had a greater proportion of patients receiving l-leucovorin/5-fluorouracil than Group A (8 patients vs none, P < 0.05).
Recent advances in surgical innovations and the utilization of new chemotherapeutic agents may have led to significant improvements in the treatment outcomes for advanced colorectal cancer in Japan.
Key wordsColorectal cancer Liver resection Disease-free status Chemotherapy
- 1.The Editorial Board of the Cancer Statistics in Japan (editor). Cancer statistics in Japan 2007. Foundation for Promotion of Cancer Research (FPCR), Japan; 2007.Google Scholar
- 2.Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamaguchi Y, et al. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and l-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. Jpn J Clin Oncol 2007;37:686–691.PubMedCrossRefGoogle Scholar
- 4.U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2004 incidence and mortality. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2007.Google Scholar
- 19.Vamvakas L, Kakolyris S, Kouroussis C, Kandilis K, Mavroudis D, Ziras N, et al. Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. Am J Clin Oncol 2002;25:65–70.PubMedCrossRefGoogle Scholar
- 21.Bécouarn Y, Gamelin E, Coudert B, Négrier S, Pierga JY, Raoul JL, et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patient. J Clin Oncol 2001;19:4195–4201.PubMedGoogle Scholar